The substitution of raltegravir for the NRTIs will result in some reversal of the long term
adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with
the chronic use of NRTIs. Changing the HAART regimen in patients with a sustained virological
response from a PI plus NRTI to a regimen of the PI plus raltegravir will likely result in
continued virologic efficacy.
Phase:
N/A
Details
Lead Sponsor:
Southern California Institute for Research and Education